Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Net Margin (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Net Margin for 5 consecutive years, with 15203.74% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Net Margin rose 1799143.0% year-over-year to 15203.74%, compared with a TTM value of 4064.94% through Dec 2025, up 653421.0%, and an annual FY2024 reading of 2579.03%, down 69453.0% over the prior year.
  • Net Margin was 15203.74% for Q2 2025 at SAB Biotherapeutics, up from 8669.15% in the prior quarter.
  • Across five years, Net Margin topped out at 15203.74% in Q2 2025 and bottomed at 8669.15% in Q4 2024.
  • Average Net Margin over 5 years is 922.59%, with a median of 280.77% recorded in 2022.
  • The sharpest move saw Net Margin tumbled -797092bps in 2023, then soared 1799143bps in 2025.
  • Year by year, Net Margin stood at 104.46% in 2021, then plummeted by -249bps to 364.42% in 2022, then plummeted by -1956bps to 7493.75% in 2023, then dropped by -16bps to 8669.15% in 2024, then surged by 275bps to 15203.74% in 2025.
  • Business Quant data shows Net Margin for SABS at 15203.74% in Q2 2025, 8669.15% in Q4 2024, and 2787.69% in Q2 2024.